click enter text
guidanc recap model chang
wednesday morn eli lilli provid new guidanc held
analyst meet report updat forecast provid recap
meet
estim go higher near- long-term leav solidli
posit question remain one valuat
whether high expect alreadi fulli emb robust outlook
addit detail us/eu drug compani
cover see recent initi report oct global pharmaceut
trade fundament data
upsid target
factset/wolf research price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
wednesday market open provid updat guidanc present
new guidanc guidanc came solid level modestli ahead current consensu higher
estim consensu varieti program refresh upon base
busi pipelin base busi new disclosur per se pipelin
smaller one addit data introduct parkinson diseas
drug pam continu intrigu consensu clearli
highest expect product develop previously-releas data look great need
replic phase trial includ prove drug safe long-term safeti
issu per se novel mechan absolv risk tanezumab continu seem
like wildcard us base safeti reason describ program still need prove
front studi read overal remain well-posit compani albeit one
investor expect valuat high core long-term hold big leg out-performance
stock may paus
revenu estim increas ep estim increas
depend year big chang larg driven chang
long-term trulic forecast like low includ push loe variou ex-u
geographi vs model out-year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas repres peer
pt maintain target multipl rais year-end price target
base new higher ep
page
exhibit summar lli financi guidanc vs estim
exhibit guidanc vs wr estim old new
exhibit summar lli new financi guidanc vs estim
exhibit captur chang forecast
page
oldnewprior wolf bgross marginapprox bother meffect tax rateapprox guidancewr bgross marginapprox bother meffect tax rateapprox guidancewr estim
exhibit chang wr model
high-level overview management start event recount street reaction analyst
day posit stock close point peer-lead return sinc
along note price-to-earnings multipl doubl guidanc anticip reason us price
reconfirm spin rest elanco anim health end determin method
final disposit expect margin expans beyond today guidanc
compani move farther next decad
trulic diabet pick point market share last year categori
expand see good access
page
jardianc diabet achiev clear market leadership overal class slower
expect look forward heart failur studi read begin could expand
market ada/easd guidelin updat support categori growth
taltz psoriasi product categori label data trial vs
tremfya read competit respons jnj recent report eclips trial see
verzenio breast cancer expect continu growth go forward new brand share
posit high risk patient liver met high tumor grade segment call
potenti opportun segment data come
emgal migrain earli launch payer discuss go well expect good coverag
expect meaning contribut pain portfolio import futur
growth driver compani
question think peak sale pain franchis econom tanezumab
reflect provid quantif recount driver growth term
event anticip lasmiditan regulatori decis emgal cluster headach approv
tanezumab partnership book lli portion sale top line lli
portion expens normal area
question think trulic due gener victoza oral sema
updat olumi trulic fantast run gain share even despit recent
novo launch rewind anoth driver growth realli address oral sema gener
victoza olumi approv countri talk ge ja launch
strong us dose physician experi still good whole outlook favor
atop dermat data mod-to-sever patient could also first jak categori
question expect list/net price contribut also outlook tax rate beyond
guidanc assum modest sd net declin us price due thing like continu effort patient
access tax rate certainli sustain long term floor might time
continu assess interpret treasuri reg
question lt margin profil outlook grown slower hope
outlook expect year-over-year op margin expans next sever year driven varieti
new product scale howev off-set partli spend rise young
portfolio overal jardianc like make parallel initi safeti question reced
see posit dynam new patient start import commerci event
re-inclus major formulari
question perspect ou refer price propos
speed maxim program work hh think refer price bad exposur
part low overal event note alreadi begun
trial also excit potenti nash opportun drug talk
page
high level overview management last time held day claim undergo
transform clearli happen support exampl timelin specif
time first human dose launch went last cite emgal
ultra rapid lispro specif product exampl also call success rate risen lli
success rate vs peer also call size new product
launch note consensu forecast blockbust statu global launch occur
admit first-in-class area like cgrp
slow translat side go lab patient dose work goal
regard extern innov target lli pipelin come
verzenio breast cancer data breast earli howev
proof concept data alreadi os data
adjuv would signific market expand fast enrol
pegilodecakin peg cancer armo acquisit note monotherapi activ
lung cancer trial cypress report late one trial combo pembro one nivo also
pancreat trial read futur opportun beyond includ renal cell
earli stage molecul mention read aurora-a kinas inhibitor read
prexasertib
emgal lasmiditan migrain former call episod cluster headach opportun
receiv breakthrough therapi design latter regulatori decis
lasmiditan doesnt cv like triptan differenti
tanezumab pain split excit opportun variou pain state oa lbp cancer
challeng thu far efficaci rather safeti note case type rpoa well
higher joint replac await data on-going studi seeeagerli await
full set data earli
alz dz data show deep rapid plaqu clearanc data earli ad amyloid low-
medium tau burden read
anti-tau antibodi alz dz describ tau time biomark correl close
symptom progress read out
pam parkinson diseas dementia data symptomat drug new mention
page
olumi indic expans atop derm lupu despit dupix sanofi still big unmet
medic need ad recount data ad show good efficaci top line
sle data us data doesnt look good rel pbo compar arm
better
mirikizumab psoriasi ibd psoriasi data first test ibd show
data uc report cd report
briefli mention new mealtim new basal insulin pen pump continu glucos
monitor partnership deka
trulic rewind took risk patient prior cv diseas paid
ada cant come soon enough roll data
tirzepatid slide product highlight today
work area mani year year ahead competit game chang
product show new data slide treatment analysi patient achiev
target also excit potenti weight loss also show treatment data
patient achiev weight loss note higher gi high dose caus
drop out led studi look chang titrat lower discontinu
 show futur medic meet believ abl deliv trulicity-lik patient
experi obes initi nash initi nash excit
weight loss improv diseas burden tirzepatid lower weight also improv insulin
resist also import nash biopsy-driven
question view verzenio adjuv breast continu dose benefit continu
see biolog rational might yield clinic benefit
question tirzepatid benefit narrow go say design
base titrat algorithm work confid outcom subgroup analys
encourag patient achiev normoglycemia
question tirzepatid prior data show plateau weight loss end
dose could potenti problem long-term dose term caus metabol
disturb agre plateau monitor track whether patient chang
band fall within say tirzepatid seem caus reset setpoint patient
normal weight might see show
question comment pfe recent neoaduv data ibranc kol
impress see continu dose verzenio confer advantag second
question usag evolv relat drug class tough
comment much pfe data differ drug felt continu dose may
advantag support preclin data neoaduv studi
page
shown clinic benefit diabet bullish class market penetr
product respect segment low two drug also studi combin
may opportun
question product go forward much harder replic gain
seen last separ tirzepatid enrol think speed
rate trial enrol one potenti area improv also say right think make
increment gain could difficult go forward tirzepatid design inclusion/exclus
criteria repres real-world popul also look combo also insulin
question recent data tanezumab good earlier data
problem also comment potenti convers rpoa separ
tirzepatid think cannib trulic believ pbo-adjust rate
recent tanezumab realli differ trial doesnt make much
given differ trial design three big trial read rpoa convers rpoa
measur earlier trial sure continuum anyway two doesnt
data answer question tirzepatid success inde cannib trulic
question emgal excit say verzenio seem gotten
airtim today analyst meet tirzepatid show treatment data
today dose titrat data say dont read anyth slide shown
product case tirzepatid say on-treat data inclus dose titrat
patient give confid alreadi seen good dose titrat data
question difficult get patient step dose titrat tirzepatid
weight loss reason expect less robust data titrat dose tanezumab expect
see least level rpoa tirzepatid believ could good mainten
dose initi improv upon toler dose move
dose need lower dose dont deliv given patient need offer flexibl dose
term tanezumab remain hope risk benefit remain favor talk lbp patient
gener less baselin oa perhap less rpoa
question tirzepatid like use tanezumab rpoa confer regulatori risk
cancer pain data shown tan tirzepatid hope first inject therapi patient
tanezumab data still come remain tbd cancer pain read out yet shown tanezumab
question tanezumab lli latest think underli mechan rpoa nash
valid issu biopsi present doesnt know mechan rpoa
specul rpoa measur prior trial new ground broken nash
lli reli biopsi fda publish draft guidanc recent talk biopsi
necessari diagnosi inde variabl biopsi look also
question tanezumab lbp degre rpoa would problemat say
rpoa popul potenti concern regardless indic remind
data hand moment rpoa would still need balanc
unmet medic need pain
page
question olumi see opportun bring ra us second
question chang plan bd involv pam
competit landscap look like today said launch eu go well remain confid
higher dose discuss dose ra fda indic look
well busi develop set target extern innov
molecul specif deal see take risk asset also seek
discoveri deal approach develop differ use new tool pam inde
rais profil talk today note higher risk program said pathway
well understood note symptomat drug success rate higher disease-modifi
question neurosci comfort collect current asset
neurosci rank term bd say never satisfi area enough
necessarili rank higher lli bd scale partli lot intern capabl
question jardianc price play indic come line like heart failur
also retinopathi tirzepatid remain optimist heart failur function data read
price say earli specul might play without data
tirzepatid confirm seen retinopathi
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total prasugrel share total total primari taltz ixekizumab olumi baricitinib jak tanezumab anti-ngf pain galcanezumab anti-cgrp migrain total specialti total earli stage factor- total anim total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
